The first reduction for a major drug treating pulmonary arterial hypertension, the second reduction for a key cancer drug a small reduction for a biosimilar in the October round of price disclosure cuts. …
Latest Video
New Stories
-
Ex-AusBiotech CEO appointed to lead peak body for manufacturing technology sector
April 16, 2024 - - Latest News -
Plan recommends greater 'transparency and accountability of health procurement processes'
April 16, 2024 - - Latest News -
HTA review extended by three weeks following reference committee request
April 16, 2024 - - Latest News -
Gilead celebrates 25 years in Australia and NZ with official office opening
April 16, 2024 - - Latest News -
Seaport Therapeutics receives $100 million in funding to maximise Monash invention
April 15, 2024 - - Australian Biotech -
Who more than these children should expect direct action from their health minister?
April 15, 2024 - - Latest News -
David Seymour confirms that pseudoephedrine will be back on pharmacy shelves for Winter
April 15, 2024 - - Latest News